CAMBRIDGE, Mass., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ: SAGE ) today announced that it will participate in three upcoming investor conferences in November:
- 24 th Annual Credit Suisse Healthcare Conference on Tuesday, November 10 at 3:30 p.m. MT in Scottsdale, Ariz.
- Stifel Healthcare Conference 2015 on Wednesday, November 18 at 11:45 a.m. ET in New York City.
- Goldman Sachs US Emerging/SMID Cap Growth Conference on Thursday, November 19 at 12:30 p.m. ET in New York City.
Live webcasts of the presentations can be accessed on the investor page of SAGE's website at investor.sagerx.com . Replays of the webcasts will also be archived for up to 30 days on SAGE's website following the conferences.
About Sage Therapeutics
Sage Therapeutics (NASDAQ: SAGE ) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. SAGE has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. SAGE's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. SAGE is developing its next generation modulators, including SAGE-217 and SAGE-689, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com .
Investor Contact: Paul Cox, Sage Therapeutics paul.cox@sagerx.com 617-299-8377 Media Contact: Dan Budwick, Pure Communications dan@purecommunicationsinc.com 973-271-6085